Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06577025
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
A Study of Different Sequences of Cilta-cel Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab Bortezomib Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel Cilta-cel Talquetamab SC in Combination With Daratumumab SC Tal-D and Teclistamab SC in Combination With Daratumumab SC Tec-D Following Induction With Daratumumab Bortezomib Lenalidomide and Dexamethasone DVRd in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
aMMbition
Brief Summary:
The purpose of this study is to evaluate the rate of response how effectively treatment is working with signs of potential cure at 5 years after the start of induction treatment This is defined as a composite of sustained at least 2 years minimal residual disease MRD negativity with complete responsestringent complete response CRsCR and a positron emission tomographycomputed tomography PETCT scan that does not show any signs of cancer at 5 years MRD negativity and CRsCR is defined as no detectable signs of remaining cancer cells after the treatment This study will also characterize how well the treatments administered work in the study through progression-free survival PFS PFS is defined as the length of time during and after the treatment of a disease that a participant lives with the disease but it does not get worse
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None